Wyeth PFE

  1. All
  2. Commentary
  3. Headlines
    1. Ex- Wyeth head Poussot to join Roche board, rather than Sanofi

      Headlines

      Fri, 12 Dec 2014

      PARIS, Dec 12 (Reuters) - Former Wyeth chief executive Bernard Poussot looks to be out of the running to take over as the next boss of French drugmaker Sanofi, as Swiss rival Roche said on Friday he was joining its board.

    2. We're Skeptical of a Potential Zoetis Sale Despite Pershing Square's Reported 10% Stake

      Commentary

      Tue, 11 Nov 2014

      companies control 68% of the market versus just 29% for the top five human-pharmaceutical companies. During the Pfizer/ Wyeth and Merck/Schering mergers, regulators forced significant divestitures of animal-health products while leaving the remaining

    3. SNY down over 10% in two days

      Commentary

      Wed, 29 Oct 2014

      it makes sense to own a number of pharmas. Only once have I experienced a dividend cut from a pharma - when Pfizer bought Wyeth they halved their dividend. Other than that, my pharmas just keep sending me money. I watched SNY fall yesterday, today

    4. A Shift in Health-Care M&A Activity

      Headlines

      Sat, 23 Aug 2014

      lot of salespeople. You can cut some R&D. You can streamline manufacturing. It's what Pfizer has done in the past with Wyeth , Pharmacia, and Warner-Lambert. There were secondary drivers, including expanding Pfizer's pipeline. The pipeline as

    5. Investor or Speculator?

      Headlines

      Tue, 12 Aug 2014

      Progenics Pharmaceuticals PGNX and partner Wyeth WYE announced Thursday that both the Food and Drug Administration ..... acceptance triggers a $5 million milestone payment from Wyeth to Progenics and could result in additional milestone and

    6. ‘Trying to Recapture the Magic’: The Strategy Behind the Pharma M&A Rush

      Headlines

      Fri, 30 May 2014

      string of big-ticket mergers. It bought Warner-Lambert in 2000 for $90 billion, Pharmacia in 2003 for $60 billion and Wyeth in 2009 for $68 billion. As a result of those mergers, Pfizer found itself saddled with some businesses it didn’t want

    7. Mead Johnson Lowering Prices on Some China Products by 7%-15%; Maintaining Fair Value Estimate

      Commentary

      Wed, 10 Jul 2013

      China by 7%-15%, echoing changes made by competitors Danone BN (decreasing prices by 5%-20%), Nestle NESN (its Wyeth unit, acquired from Pfizer PFE , is lowering prices by 6%-20%), Abbott Laboratories ABT (4%-12%), and local competitors

    8. Pfizer Reports Strong 2Q as Cost-Cutting Helps Offset Generic Competition to Lipitor

      Commentary

      Tue, 31 Jul 2012

      we believe the majority of the efficiency improvements stem from Pfizer's plan to save $4 billion annually following the Wyeth acquisition. We believe Pfizer is likely to achieve this goal. Additionally, Pfizer reaffirmed its full-year 2012 earnings

    9. Pfizer's 1Q In Line as Cost-Cutting, Diversified Portfolio, Share Buybacks Offset Patent Losses

      Commentary

      Tue, 3 May 2011

      we believe Pfizer is improving its operating structure and will hit its target of $4 billion in annual cost savings from the Wyeth acquisition by 2012. Additionally, Pfizer repurchased $2.2 billion of shares in the first quarter, reducing its share

    10. Wyeth Acquisition Helps Pfizer Post In-Line 4Q; Share-Repurchase Program Signals Undervaluation

      Commentary

      Tue, 1 Feb 2011

      operationally by 7% year over year, as the Wyeth acquisition drove all the growth. Excluding Wyeth , sales would have declined 7% from the prior ..... the higher share count and costs related to Wyeth acquisition weighed on earnings growth. We

    « Prev12345Next »
    Content Partners